AzTrials
AzTrials

Child ObesityNCT04525560

Efficacy, Safety and Tolerability of Different Bowel Preparation Before Colonoscopy in Children Over 2 Years Old

A study testing PEG-ELS-S and PEG-ELS-L in people with Child Obesity and Bowel Preparation, run by Children's Hospital of Fudan University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Electronic colonoscopy plays an important role in the diagnosis and follow-up of intestinal diseases in children. Read more about this study

Who is it for?
Ages 2 to 22 years
Conditions the study is for
Child Obesity, Bowel Preparation
What is being tested?
PEG-ELS-S and PEG-ELS-L
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
315 participants
Where
1 siteChina
Study dates
1 Aug 2020to 30 May 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 22 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Newly diagnosed children in Department of Gastroenterology at Children's Hospital of Fudan University
  • According to the indications of electronic colonoscopy, colonoscopy was performed for the first time
  • Age: 2-22 years old

Who cannot join

  • Having contraindications of electronic colonoscopy
  • Having contraindications of general anesthesia
  • Previous abdominal surgery
  • Chronic constipation
  • There is evidence of intestinal stenosis and gastrointestinal malformation
  • Laxatives or drugs in the intestinal preparation protocol of this study have been used before bowel preparation
  • Disagree the use of the bowel preparation protocol developed in the study

Trial locations and contacts

1 site in 1 country.

China1 site
  • Children's hospital of Fudan university

    Shanghai, Shanghai Municipality, 201102

Other trials in China

About this study

Electronic colonoscopy plays an important role in the diagnosis and follow-up of intestinal diseases in children.

Read the detailed description

The adequacy of bowel preparation before colonoscopy is particularly important for the visualization of intestinal mucosa under colonoscopy. Some studies have shown that bowel preparation must be customized according to the age, weight and clinical status of the child. However, there is no internationally recognized standard scheme for pediatric intestinal reserve. In pediatric clinical trials, polyethylene glycol with electrolyte solution (PEG-ELS) is more effective than bisacodyl, folium sennae and magnesium citrate. PEG-ELS is an electrolyte balanced isotonic solution, which can be used to clean the intestinal tract by large volume irrigation. Polyethylene glycol 4000 is a long-chain linear polymer, which can hardly absorb and decompose after oral administration. It can effectively increase the composition of intestinal fluid, stimulate intestinal peristalsis, cause watery diarrhea, and achieve the purpose of cleaning the intestine. The inorganic salt composition and proper amount of water in the formula ensure the balance of water and electrolyte exchange between intestinal tract and body fluid. In this study, PEG-ELS short protocol and long protocol were selected for intestinal preparation, and the effectiveness and safety of different intestinal preparation protocols under electronic colonoscopy for children over 2 years old were compared.

Being tested
PEG-ELS-S, PEG-ELS-L
Keywords
Child, Electronic colonoscopy, bowel preparation, polyethylene glycol with electrolyte solution
Medical subject headings
Pediatric Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PEG-ELS-SOther

    2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.

  • PEG-ELS-LOther

    PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.

Study groups in NCT04525560
Study groupRoleWhat they receive
PEG-ELS-SExperimentalThe dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
Receives: Other: PEG-ELS-S
PEG-ELS-LActive comparatorThe dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
Receives: Other: PEG-ELS-L

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bowel cleansing

    Bowel cleansing was assessed by Boston bowel preparation scale (BBPS). The scores of left, middle and right colon were added up to the total score of BBPS, with the lowest score of 0 and the highest score of 9. The score of 8-9 represents excellent bowel preparation, 6-7 represents good, 4-5 represents average, and 0-3 represents poor. Excellent and good for intestinal preparation are qualified, general and poor for intestinal preparation are unqualified.

    Measured: During the operation of electronic colonoscopy (about 15 min )

Secondary outcomes (6)
  1. Compliance with polyethylene glycol with electrolyte solution (PEG-ELS)

    This variable is a binary variables (good/poor). Poor compliance was defined as PEG-ELS dosage less than 75% of the prescribed dose. Good compliance was defined as PEG-ELS dosage more than 75% of the prescribed dose. Prescribed dose and actually oral dose were recorded by nurse.

    Measured: During bowel preparation (about 24 hours)

  2. Adverse reactions receiving polyethylene glycol with electrolyte solution

    This variable is a binary variables (Yes/No). The variable would be set to "Yes" as any adverse reactions including Nausea, vomiting, abdominal distension, abdominal pain or allergic to PEG-ELS appeared during bowel preparation.

    Measured: During bowel preparation (about 24 hours)

  3. Rate of nasal feeding PEG-ELS

    Rate of nasal feeding PEG-ELS. Nasogastric feeding is recommended for those who cannot complete the prescribed amount.

    Measured: During bowel preparation (about 24 hours)

  4. Enema rate before colonoscopy

    At 8 am on the day of electronic colonoscopy, no food and water were given from 8 am. At 11 am on the day of colonoscopy, the last assessment of stool was conducted. If the Bristol stool form scale (BSFS) ≤ 5 points, colonoscopy should be cancelled and bowel preparation time should be prolonged; if BFSF = 6 points, Warm normal saline (50 ml/kg) was given for enema; if BFSF = 7 points, no enema.

    Measured: immediately before colonoscopy

  5. Times of washing under colonoscopy

    If the visual field is not clear, it should be washed during the operation of electronic colonoscopy.

    Measured: During the operation of electronic colonoscopy (about 15 mins)

  6. Adverse events

    It is a repeated measured variable. This variable is a binary variables (Yes/No). The variable would be set to "Yes" as any adverse reactions. An adverse event refers to the event that occurs after a patient in a clinical study accepts a research-based product, which does not necessarily have a causal relationship with the test product. Adverse events are diseases, signs or symptoms (including abnormal laboratory results) that occur or worsen during the course of the study.

    Measured: up to 30 minutes after colonoscopy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2020
  2. Study start1 Aug 2020
  3. Primary completion30 May 2021
  4. Study completion30 May 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
315 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04525560
Sponsor's protocol ID
BP/2+
Status last verified
Oct 2021
First submitted
21 Aug 2020
Last updated
11 Oct 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing PEG-ELS-S and PEG-ELS-L in people with Child Obesity and Bowel Preparation, run by Children's Hospital of Fudan University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bowel cleansing (time frame: During the operation of electronic colonoscopy (about 15 min )). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in